Enanta Pharmaceuticals, Inc.
ENTA Healthcare Biotechnology
Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024. In the quarter to June 2026, revenue fell 21.6%, EPS grew 21.2% and free cash flow fell 157.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow ENTA
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Sep '25 | Sep '24 | Sep '23 | Sep '22 | Sep '21 | Sep '20 | Sep '19 | Sep '18 | Sep '17 | Sep '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
188.86 | 248.79 | 369.91 | 249.23 | 244.00 | 386.65 | 335.24 | 308.73 | 223.67 | 210.08 |
Receivables |
6.88 | 38.65 | 39.62 | 49.04 | 60.83 | 36.53 | 51.31 | 67.21 | 10.61 | 12.84 |
Total current assets |
204.34 | 299.85 | 422.79 | 311.71 | 319.02 | 436.84 | 401.85 | 380.39 | 237.82 | 232.16 |
Property, Plant, Equpment (Net) |
35.40 | 32.69 | 11.92 | 6.17 | 5.94 | 8.60 | 10.93 | 8.37 | 8.05 | 8.00 |
Long-Term Investments |
— | — | — | 29.29 | 108.42 | 32.63 | 65.01 | 16.39 | 70.04 | 32.12 |
Long Term Assets (Tax, Deferred) |
— | — | — | — | — | 0.35 | 11.34 | 8.38 | 10.12 | 8.39 |
Long-term assets (Other) |
3.45 | 3.45 | 4.77 | 4.66 | 0.70 | 0.70 | 0.70 | 0.70 | 0.61 | 0.61 |
Total non-current assets |
76.40 | 76.80 | 39.48 | 63.70 | 119.77 | 49.30 | 87.98 | 33.84 | 88.82 | 49.12 |
Total Assets |
280.73 | 376.65 | 462.28 | 375.41 | 438.79 | 486.13 | 489.83 | 414.23 | 326.64 | 281.28 |
Accounts Payable |
1.95 | 8.00 | 4.10 | 6.00 | 9.54 | 5.74 | 6.69 | 4.75 | 3.71 | 3.38 |
Accrued Expenses |
12.75 | 13.55 | 18.34 | 20.94 | 22.43 | 14.16 | 15.92 | 9.89 | 7.97 | 4.51 |
Current Part of Taxes to Pay |
— | — | — | — | — | — | 0.00 | 1.39 | 9.30 | 0.00 |
Other current liabilities |
30.71 | 34.46 | 35.08 | 20.94 | 22.43 | 14.16 | 15.92 | 9.89 | 7.89 | 4.44 |
Total current liabilities |
48.56 | 57.54 | 62.79 | 29.83 | 36.17 | 24.16 | 22.61 | 16.03 | 20.98 | 7.89 |
Liabilities (Preferred Stock) |
1.31 | 1.35 | 1.42 | 1.42 | 1.51 | 1.48 | 1.63 | 1.63 | 0.76 | 0.16 |
Non-current Liabilities (Other) |
111.39 | 135.01 | 160.09 | 0.45 | 0.56 | 1.08 | 3.10 | 2.90 | 3.22 | 3.29 |
Total non-current liabilities |
167.46 | 190.30 | 182.75 | 24.25 | 3.19 | 6.40 | 4.73 | 4.52 | 3.98 | 3.45 |
Total liabilities |
216.02 | 247.84 | 245.54 | 54.08 | 39.36 | 30.55 | 27.34 | 20.55 | 24.96 | 11.34 |
Additional Paid In Capital |
469.77 | 451.34 | 424.69 | 398.03 | 351.03 | 326.96 | 298.41 | 276.53 | 256.24 | 242.08 |
Common Stock (Net) |
0.21 | 0.21 | 0.21 | 0.21 | 0.20 | 0.20 | 0.20 | 0.19 | 0.19 | 0.19 |
Retained Earnings |
(404.93) | (323.04) | (206.99) | (73.18) | 48.58 | 127.57 | 163.74 | 117.36 | 45.36 | 27.65 |
Common Equity (Total) |
64.72 | 128.81 | 216.74 | 321.33 | 399.43 | 455.58 | 462.49 | 393.68 | 301.68 | 269.94 |
Shareholders Equity (Total) |
64.72 | 128.81 | 216.74 | 321.33 | 399.43 | 455.58 | 462.49 | 393.68 | 301.68 | 269.94 |
Shareholders Equity and Liabilities (Total) |
280.73 | 376.65 | 462.28 | 375.41 | 438.79 | 486.13 | 489.83 | 414.23 | 326.64 | 281.28 |
Shares (Common) |
21.39 | 21.19 | 21.06 | 20.79 | 20.24 | 20.08 | 19.70 | 19.40 | 19.12 | 19.04 |
Shareholders Equity (Tangible) |
64.72 | 128.81 | 216.74 | 321.33 | 399.43 | 455.58 | 462.49 | 393.68 | 301.68 | 269.94 |
Net Debt |
(188.86) | (248.79) | (369.91) | (249.23) | (244.00) | (386.65) | (335.24) | (308.73) | (223.67) | (210.08) |
Total Debt |
— | — | 222.44 | 26.69 | 6.84 | 9.58 | 1.83 | 1.92 | 1.22 | 0.69 |